Adlai Nortye (NASDAQ:ANL) Shares Gap Up – Still a Buy?

Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) shares gapped up prior to trading on Friday. The stock had previously closed at $10.88, but opened at $11.89. Adlai Nortye shares last traded at $11.4380, with a volume of 7,265 shares changing hands.

Analysts Set New Price Targets

A number of research firms recently weighed in on ANL. Jefferies Financial Group raised Adlai Nortye to a “strong-buy” rating in a research note on Monday, October 5th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Adlai Nortye in a research report on Monday. Loop Capital set a $49.00 price target on shares of Adlai Nortye in a research note on Tuesday, September 8th. Wall Street Zen raised Adlai Nortye from a “hold” rating to a “buy” rating in a report on Saturday, October 3rd. Finally, Cantor Fitzgerald assumed coverage on Adlai Nortye in a research report on Monday, June 22nd. They set an “overweight” rating for the company. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Adlai Nortye has a consensus rating of “Moderate Buy” and a consensus price target of $29.50.

Adlai Nortye Stock Down 5.1%

The stock’s fifty day simple moving average is $14.49 and its 200 day simple moving average is $12.72.

Insider Activity at Adlai Nortye

In other Adlai Nortye news, Director Ping Ji sold 10,000 shares of the firm’s stock in a transaction on Wednesday, September 30th. The stock was sold at an average price of $15.99, for a total value of $159,900.00. Following the completion of the sale, the director owned 121,453 shares of the company’s stock, valued at approximately $1,942,033.47. This trade represents a 7.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Xiaofeng Ye sold 6,000 shares of the firm’s stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $13.98, for a total transaction of $83,880.00. Following the transaction, the chief financial officer directly owned 153,424 shares of the company’s stock, valued at approximately $2,144,867.52. This trade represents a 3.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 26,881 shares of company stock valued at $411,060.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of ANL. SmartHarvest Portfolios LLC increased its holdings in Adlai Nortye by 8.5% in the first quarter. SmartHarvest Portfolios LLC now owns 16,367 shares of the company’s stock valued at $113,000 after buying an additional 1,279 shares during the last quarter. Renaissance Technologies LLC bought a new position in shares of Adlai Nortye in the first quarter valued at $457,000. Seven Fleet Capital Management LP acquired a new stake in Adlai Nortye during the 2nd quarter worth about $1,302,000. ADAR1 Capital Management LLC purchased a new stake in shares of Adlai Nortye in the first quarter valued at $816,000. Finally, Affinity Asset Advisors LLC acquired a new position in Adlai Nortye in the 1st quarter valued at approximately $1,140,000. Institutional investors and hedge funds own 35.21% of the company’s stock.

About Adlai Nortye

Adlai Nortye Ltd. (NASDAQ: ANL) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cancer and other serious diseases. The company’s research and development programs are centered on immuno-oncology and targeted therapies intended to address unmet medical needs.

Adlai Nortye’s pipeline has included buparlisib, an oral pan-PI3K inhibitor being studied in oncology, as well as AN0025, an investigational EP4 antagonist designed to affect pathways involved in tumor growth and immune response.